British pharma AstraZeneca plc has announced it will purchase MedImmune Inc. for $15.6 billion. AstraZeneca will pay $58 per share in cash, representing a premium of approximately 53% to MedImmune's share price on April 11, the day before news broke that the U.S. biotech company was for sale. The deal is expected to close in June.


Comments